MedPage TodayOncoBreak: DES Risk Lives On; CAR T-Cell News; Fake Cancer CausesMedPage TodayA drug initially developed to boost cognition and memory may also unleash stress-response proteins that can kill prostate cancer cells. (University of California… Continue reading
BeyondSpring (BYSI) vs. Editas Medicine (EDIT) Head to Head AnalysisBangaloreWeeklyIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic aci… Continue reading
Scrip |
Ferring Makes Foray Into Gene Therapy With FKD Pact
Scrip Executive Summary. The Swiss company’s CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland’s FKD highlights the transformation that Ferring is undergoing. Already Registered? Sign in to continue … |
Friedreich’s Ataxia News |
UK Pilot Study to Evaluate Effects of Stem Cell Therapy in Friedreich’s Ataxia Patients
Friedreich’s Ataxia News The clinical benefits of stem cell therapy in Friedreich’s ataxia patients will be assessed in a small pilot study at the University of Bristol in the United Kingdom. Friedreich’s ataxia (FA) is a rare neurodegenerative disorder caused by mutations in … |
MIT News |
Fasting boosts stem cells‘ regenerative capacity
MIT News As people age, their intestinal stem cells begin to lose their ability to regenerate. These stem cells are the source for all new intestinal cells, so this decline can make it more difficult to recover from gastrointestinal infections or other … Adult Stem Cells Get a Boost from FastingGenetic Engineering & Biotechnology News Fasting improves stem cells‘ regenerative capacity: studyXinhua Fasting can help stem cells in the intestine to regenerateZME Science |
Myasthenia Gravis News |
#AAN2018 – Rituxan a Promising First-line Immunotherapy in Late-onset MG, Study Suggests
Myasthenia Gravis News The researchers analyzed Rituxan’s effectiveness and safety by treating six late-onset MG patients (five women and one man) with the therapy, ultimately evaluating its potential as a first-line immunotherapy. Mean age of myasthenia gravis onset was 66 … |